Dianthus Therapeutics (Dianthus Therapeutics) FCF Margin % : -1,713.16% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Dianthus Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was $-14.97 Mil. Dianthus Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.87 Mil. Therefore, Dianthus Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -1,713.16%.

As of today, Dianthus Therapeutics's current FCF Yield % is -3.48%.

The historical rank and industry rank for Dianthus Therapeutics's FCF Margin % or its related term are showing as below:

DNTH' s FCF Margin % Range Over the Past 10 Years
Min: -1308.24 Med: -673.24 Max: -455.18
Current: -1190.11

During the past 3 years, the highest FCF Margin % of Dianthus Therapeutics was -455.18%. The lowest was -1308.24%. And the median was -673.24%.

DNTH's FCF Margin % is ranked worse than
77.92% of 1046 companies
in the Biotechnology industry
Industry Median: -145.305 vs DNTH: -1190.11

Dianthus Therapeutics FCF Margin % Historical Data

The historical data trend for Dianthus Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics FCF Margin % Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

-673.24

-455.18

-1,308.24

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial			-755.74	-2,163.45	-	-2,596.06	-1,713.16

Competitive Comparison of Dianthus Therapeutics's FCF Margin %

For the Biotechnology subindustry, Dianthus Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dianthus Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's FCF Margin % falls into.

Dianthus Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Dianthus Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-36.971	/	2.826
	=	-1,308.24 %

Dianthus Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-14.973	/	0.874
	=	-1,713.16 %

Dianthus Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023